Sulforaphane for preventing new melanoma in survivors
Part of Cancer, Skin clinical trials.
This trial tests whether sulforaphane, a natural compound found in broccoli and other cruciferous vegetables, can help prevent new melanoma skin cancers in people who have already had melanoma. You must have at least 3 unusual-looking moles and be at low risk of your prior cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had early-stage melanoma (stage 0, I, II, or III with low risk of relapse within the next year)
- You have at least 3 unusual-looking moles (at least 5 mm wide, with a flat part and features like blurry edges or mixed colors)
- You are 18 years or older
- You are not currently on or haven't recently had targeted therapy or immunotherapy for melanoma
- You are not pregnant, and you have no known allergy to broccoli or similar vegetables
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving two drugs (SHR-1701 and famitinib) before surgery, followed by additional treatment based on how well the tumor responds, can help patients with mucosal melanoma (a rare skin cancer in moist areas like the mouth or nose). The goal is to shrink the tumor and improve outcomes after surgery.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.